linjc16/ctgov huggingface dataset:
A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to investigate the clinical value of [18F]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide（18F-AlF-NOTA-octreotide ） positron emission tomography / computed tomography (PET/CT) in patients with neuroendocrine neoplasms (NENs).

Detailed Description
-----------------
18F-AlF-NOTA-octreotide is a radioligand targeting the somatostatin receptor, which is widely expressed on the cell surface of NENs. The radioligand can be used for the diagnosis and stage of the NENs. A total of 5 volunteers and 60 NEN patients will be subjected to a 18F-AlF-NOTA-octreotide PET/CT scan. The uptake of 18F-AlF-NOTA-octreotide in organs and tumor lesions will be quantified as Standardized Uptake Values (SUVmax/SUVmean).

Official Title
-----------------
A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms

Conditions
-----------------
Neuroendocrine Neoplasm

Intervention / Treatment
-----------------
* Drug: 18F-AlF-NOTA-octreotide
* Device: PET/CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically and/or clinically confirmed and/or suspicious of NEN. Signed informed consent. Exclusion Criteria: Claustrophobia (unable to accept PET/CT scanning) Pregnant or breast-feeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 18F-AlF-NOTA-octreotide PET/CT<br>One injection of the radioligand 18F-AlF-NOTA-octreotide | Drug: 18F-AlF-NOTA-octreotide<br>* One injection of 18F-AlF-NOTA-octreotide<br>* Other names: 18F-IMP466;Device: PET/CT<br>* Following injection of 18F-AlF-NOTA-octreotide the participants will be subjected to whole body PET/CT<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 18F-AlF-NOTA-octreotide PET/CT imaging of patients with Neuroendocrine Neoplasms | The radioligand 18F-AlF-NOTA-octreotide can be used to visualize neuroendocrine neoplasms | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 18F-AlF-NOTA-octreotide PET/CT prognostic factor for overall and disease specific survival | The uptake of the 18F-AlF-NOTA-octreotide in neuroendocrine neoplasm lesions (quantified as Standard Uptake Values) is associated with overall and disease specific free survival (PFS) neuroendocrine neoplasms | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
18F-AlF-NOTA-octreotide
3D Echocardiography Managing Infantile Pompe's Disease

Study Overview
=================
Brief Summary
-----------------
Pompe's disease, also known as glycogen storage disease type II, is a genetic disorder due to deficiency of acid glucosidase (GAA), which results in lysosomal glycogen storage in various tissues. Very low levels of GAA usually present in infancy, lead to a progressive cardiac and skeletal muscle disorder and death before age 1 year. Most infants develop massive hypertrophic cardiomyopathy which progresses to dilated cardiomyopathy and cardiorespiratory arrest. 3D echocardiography can be a simple, non-invasive method of following cardiac disease progression in infantile Pompe's disease.

Detailed Description
-----------------
We report the utilization of real-time 3D echocardiography and new in-line software to calculate cardiac mass, volume and function in two cases of infantile Pompe's Disease. Furthermore, the multi-dimension cine loop showed the severity of cavity obliteration during the cardiac cycle. We present 2 cases seen at our institution between January - February, 2005 in infants ages 1 and 5 months, both with cardiac signs as initial presentation. The younger infant had cardiomegaly since birth and was hospitalized briefly for respiratory distress at 1 month. The older infant, diagnosed at 4 months with hypertrophic cardiomyopathy, was hospitalized after cardiac arrest one month later. Both children had various tests done during the course of diagnosis and treatment, including GAA enzyme assay, cardiac catheterization, endomyocardial biopsy, developmental assessment, genetic evaluation, EKG, CXR and echocardiography.

Official Title
-----------------
Utilization of 3D Echocardiography in the Management of Infantile Pompe's Disease: Two Case Reports

Conditions
-----------------
Congenital Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infant seen at Children's Healthcare of Atlanta, Egleston January - February, 2005 Infantile Pompe's Disease Exclusion Criteria: Those who do not meet inclusion criteria
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pediatric, cardiac, Infantile Pompe's Disease, 3D Echocardiography
VerifyNow French Registry

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effect of clopidogrel or aspirin reactivity as measured by a point-of-care platelet function assay on thrombotic or bleeding events after percutaneous coronary intervention (PCI) with drug eluting or bare metal stent. Methods: Platelet reactivity on clopidogrel and aspirin therapy is measured before PCI with VerifyNow (Accumetrics Inc.,San Diego, CA, USA) P2Y12 or aspirin assay respectively in 1000 consecutive patients from 20 centers in France undergoing coronary angioplasty with stent. Exclusion criteria are: Acute myocardial infarction, treatment with vitamin K antagonists and the use of antiGP2b3a before PCI. All patients are pre-treated with clopidogrel and aspirin. Non-response to aspirin or clopidogrel is determined according to the result of the VerifyNow assay (cut off : < 15 % for P2Y12 and > 550 ARU for aspirin). The primary end point is the occurrence of definite or probable stent thrombosis (ARC definition) and the secondary end-points include global and cardio-vascular mortality, non fatal myocardial infarction and major bleeding. A clinical evaluation is scheduled at discharge and by telephone contact at one month and one year.

Official Title
-----------------
Evaluation of the Occurence of Thrombotic and Bleeding Events After Coronary Angioplasty With Stent According to Aspirin and Clopidogrel Platelet Reactivity Assessed by a Point of Care Assay in the Cathlab (the Verifynow French Registry)

Conditions
-----------------
Stent Thrombosis, Clopidogrel, Aspirin, Bleeding, Angioplasty

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Coronary angioplasty with stent Exclusion Criteria: Use of AGP2b3a Acute myocardial infarction No aspirin and clopidogrel pretreatment Use of AVK Aspirin or clopidogrel contre-indication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stent thrombosis |  | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality, cardio-vascular mortality, non fatal Myocardial infarction, urgent coronary revascularisation , re-hospitalization, severe bleeding |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stent thrombosis, clopidogrel, aspirin, bleeding, coronary, angioplasty
Closure of Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER

Study Overview
=================
Brief Summary
-----------------
The purpose of this feasibility study is to investigate the safety of the AMPLATZER® Membranous VSD Occluder for the treatment of hemodynamically significant Perimembranous Ventricular Septal Defects.

Conditions
-----------------
Membranous Ventricular Septal Defects

Intervention / Treatment
-----------------
* Device: AMPLATZER Membranous VSD Occluder


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with hemodynamically significant Perimembranous ventricular septal defects Exclusion Criteria: Patients < 8 kg Supracristal ventricular septal defects Left ventricle to right atrium shunting Prolapse of the aortic valve Right to left shunting through the defect Perimembranous VSD with an aneurysm and multiple shunts which can not be successfully closed with one device Patients with <2mm aortic rim Sepsis (local/generalized) Complex heart lesions such as atrioventricular canal defect or Tetralogy of Fallot. Patients who are ASA intolerant Unable to be followed for the duration of the clinical trial Inability to obtain informed consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Device: AMPLATZER Membranous VSD Occluder<br>* Device closure with the AMPLATZER Membranous VSD Occluder<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Closure of perimembranous Ventricular Septal Defects |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
membranous, ventricular, septal, defect, VSD
Difference of Information Gain Between Video-base and Doctor Interview After Preanesthetic Visit

Study Overview
=================
Brief Summary
-----------------
To investigate the differenec of patients' satisfaction and information gain betweem face-to-face interview and video introduction

Detailed Description
-----------------
We made up a video which showed the type, the method, the risk, and the benefit of all anesthesia with words, pictures, and image. A study nurse will ask the will of patients. The patients enrolled in the study will be randomly divided into traditional group(control group) and study group(study group). The study group will watch the video at first, then our anesthesiologist visit the patient. The control group will receive traditional anesthesiologist visit. After doctors' visit, the patients have to complete a test and a questionnaire. The patients who don't participate in the study will have traditional visit and no test.

Official Title
-----------------
Difference of Information Gain Between Video-base and Doctor Interview After Preanesthetic Visit

Conditions
-----------------
Anesthesia

Intervention / Treatment
-----------------
* Other: video-assisted pre anesthesia explain


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All adult patients were included who were scheduled to undergo elective surgery Exclusion Criteria: Postoperative stay in the intensive care unit was expected or unexpected.,Repeated general anesthesia had been performed in the previous 6 months,ASA classification was more than or equal to III,There were pronounced cognitive and or speech barriers
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Single Group Assignment
Interventional Model Description: simple compare of information gain between traditional visit and video-assisted visit
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: traditional vist<br>Patients receive traditional anesthesiologist visit | |
| Experimental: video-assisted<br>Patients watch the video, then an anesthesiologist visit | Other: video-assisted pre anesthesia explain<br>* Anesthesiologist will visit all study patients, and only the experimental group will read the video.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| inform gain analysis | The score of test would represent the inform gain of patient | after every 100 effective data or 1 year, analyzed the data | 
| satification anaylsis | The score of questionnaire represent the ratification of patient | after every 100 effective data or 1 year, analyzed the data |
Surveillance of Rotavirus Gastroenteritis

Study Overview
=================
Brief Summary
-----------------
Epidemiological studies have shown the diversity of resistance genotypes and the evolution of their prevalence in the paediatric population. This large study conducted in a context of very low vaccination coverage will generate more precise data on the natural epidemiological evolution of rotavirus, notably the G9 genotype, which has appeared relatively recently. This study will allow us to identify and document rare or unusual strains of human or animal origin. The complete genetic characterization of these strains will also make it possible to study their ability to recombine and to assess the risk of emergence. Among these still rare strains, the investigators are particularly monitoring G12 rotavirus, whose ability to recombine raises the risk of emergence. For at least one of the centres taking part in the study, the paediatric population studied will be given strong vaccination coverage. It will be extremely interesting to compare the results obtained in the vaccinated population with non-vaccinated children to assess the impact of this vaccination on the distribution of rotavirus genotypes

Official Title
-----------------
Epidemiological Surveillance of Rotavirus Gastroenteritis With a Perspective of Vaccination

Conditions
-----------------
Gastroenteritis

Intervention / Treatment
-----------------
* Biological: stool samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children hospitalized or consulting in one of the participating centres since January 2007 for acute gastroenteritis (AGE). AGE is defined by at least 3 soft or liquid stools or at least 3 bouts of vomiting within 24 hours or one of the following signs - diarrhoea or vomiting accompanied by at least 2 additional symptoms among diarrhoea or vomistin, abdominal pain, fever. Exclusion Criteria: Children older than 5 years. Children presenting chronic diarrhoea (> 2 weeks). Children presentant immune deficiency. Children presenting nosocomial gastroenteritis. The nosocomial nature will be determined by the onset of acute diarrhoea occuring after 48 hours following admission

Ages Eligible for Study
-----------------
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PATIENT<br> | Biological: stool samples<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of viral strains of rotavirus |  | through the completion study an average 10 years |
Evaluation of the Success Rate of Immediately Loaded Implants

Study Overview
=================
Brief Summary
-----------------
Evaluation of the success rate of immediately loaded implants based on: condition of the gingiva stability of the implants evaluation of the RXs questionnaires

Official Title
-----------------
Evaluation of the Success Rate of Immediately Loaded Implants

Conditions
-----------------
Dental Implants

Intervention / Treatment
-----------------
* Procedure: Evaluation of the success rate of implants
* Procedure: Questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with immediately loaded implants

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients with immediately loaded implants.<br> | Procedure: Evaluation of the success rate of implants<br>* Evaluation of the success rate of implants will be followed.<br>Procedure: Questionnaires<br>* Questionnaires will be used<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Success of implants |  | Continuous follow-up | 
| Prothetic complications |  | Continuous follow-up | 
| Opinion of the patient |  | Continuous follow-up |
Regulation of Human Intestinal Bile Acid Transport in Health and Disease

Study Overview
=================
Brief Summary
-----------------
This study investigates distribution and regulation of bile acid transport in the human intestine.

Official Title
-----------------
Regulation of Human Intestinal Bile Acid Transport in Health and Disease

Conditions
-----------------
Gastrointestinal Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Veterans, healthy, scheduled for screening colonoscopy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
THE IMPACT OF COVID-19 AMONG OBESE PATIENTS

Study Overview
=================
Brief Summary
-----------------
BACKGROUND: Stay-at-home orders in response to the Coronavirus 2 (SARSCoV-2) have forced abrupt changes to daily routines. The aim of our study is to evaluate the impact of the Stay-at-home orders on the waiting list for bariatric surgery in our Department of Medical and Surgical during covid-19 pandemic. MATERIALS AND METHODS: In this observational retrospective study, from the 9th of March to 18th May 2020, the patients of our Department were invited to answer to a 14-questions multiple-choice questionnaire relative to weight changes, working activity, daily exercise, dietary behaviors, and conditions potentially impacting the nutritional choices

Official Title
-----------------
HOW THE IMPACT OF COVID-19 HOME STAY ORDERS IS AFFECTING THE PHYSICAL, MENTAL AND FINANCIAL HEALTH AMONG OBESE PATIENTS?

Conditions
-----------------
Obesity, Morbid

Intervention / Treatment
-----------------
* Procedure: Sleeve gastrectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Alle obese patients on the waiting list for bariatric surgery in our Department of Medical and Surgical during covid-19 pandemic from March to May 2020 Exclusion Criteria: - Patients underwent bariatric surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Sleeve gastrectomy|An online survey format was administered to all obese patients on the waiting list for bariatric surgery in our Department of Medical and Surgical Sciences to obtain information about the COVID- 19 pandemic's impact on patients with obesity starting March 09, 2020 until May 18, 2020.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluate the impact of the Lock-down period on the mental and physical health of obese patients on the waiting list for bariatric surgery in our Department of Medical and Surgical Sciences during covid-19 pandemic. | we have used a 14-questions multiple-choice questionnaire relative to weight changes, working activity, daily exercise, dietary behaviors, and conditions potentially impacting the nutritional choices | March - May 2020 |
Telemedicine's Utility for Augmenting Clinical Trials and Informed Consent TACTIC

Study Overview
=================
Brief Summary
-----------------
This is a 6 year, Phase I, Clinical Research Protocol to study the feasibility of using a telemedicine system for performing research in a remote hospital system.

Detailed Description
-----------------
The UCSD Telemedicine system is a digital video camera system, which can transfer video and audio images from a clinic or emergency room to a remote place where a physician can review images in real time (as they happen). The system uses site independent software to access the camera system from multiple locations. This research study will determine if it is feasible to obtain informed consent for various types of research trials (hypothetical, non-invasive, invasive trails) via telemedicine. Inpatient assessments on participants to complete clinical research case report forms by telemedicine will also by performed.

Official Title
-----------------
Telemedicine's Utility for Augmenting Clinical Trials and Informed Consent TACTIC

Conditions
-----------------
Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male/Female, age 18 years or older Clinical neurological focal deficits consistent with stroke Time of onset 3-24 hours and with stable neurological deficit Signed Informed Consent Exclusion Criteria: Deficits known to be due to non-stroke etiology Time of onset less than 3 hours Patients unable to give consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of trials participant is enrolled into | Counting how many patients are enrolled into OTHER clinical trials using a telemedicine technique | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Telemedicine